Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2012: Case Study  

Visual evoked potentials in early diagnosis of demyelinating diseases – a case report of Devic’s disease

Ewa Langwińska-Wośko ABDEF , Kamil Szulborski ABCDEF , Karina Broniek-Kowalik ABCDEF

DOI: 10.12659/MSM.883473

Med Sci Monit 2012; 18(10): CS82-84

0 Comments

Background

Devic’s disease, or neuromyelitis optica (NMO), is an uncommon demyelinating syndrome of the central nervous system, characterized by bilateral optic neuritis and transverse acute myelitis, with no other neurological involvement. The first description of the disease was provided by Eugene Devic at the end of the 19th century in Lyon, France. NMO was previously considered to be a subtype of multiple sclerosis [1,2]. Devic’s disease is now considered as an auto-immune channelopathy [3]. Most NMO patients produce auto-antibodies against aquaporin-4 (AQP-4), also known as NMO-IgG. AQP-4 is a water channel expressed on astrocytes and in brain blood vessels [4–6]. In 2006, Wingerchuk proposed revised diagnostic criteria for NMO: 2 major criteria – optic neuritis and transverse myelitis, and at least 2 of 3 supportive criteria – MRI lesions extending over 3 vertebral segments, onset brain MRI not meeting diagnostic criteria for multiple sclerosis, and NMO-IgG seropositive status [7].

Devic’s disease most frequently affects non-Caucasian women who are older than those with multiple sclerosis. In comparison to MS, Devic’s disease also leads to more severe neurological impairment [1,8–10].

Case Report

A 21-year-old woman presented with non-specific ocular phenomena, referred as a subjective visual impairment and “blurry” vision for 3 weeks. No other complaints were reported, and the family history concerning general and ocular diseases was negative. The patient had previously been examined in 2 other ophthalmic departments and no abnormalities were found, so the patient was classified as having psychosomatic disturbances and a psychological consultation was recommended.

The patient’s best corrected visual acuity was 6/6 in both eyes on Snellen charts.

Colour vision testing using the Ishihara tables was normal.

Examinations of pupillary reflexes, anterior segment, the eye fundus and the visual field (full field 120, Humphrey) were normal. A fluorescein angiography and macular OCT (Cirrus, Zeiss) were also non-contributory.

These symptoms were still unclear, so the patient underwent electrophysiological testing by using the RetiScan RetiPort system (Roland Consult).

A multifocal ERG was performed to assess retinal function. The mfERG results were normal. Pattern visual evoked responses (PVER) were performed according to ISCEV standards and compared with normal values. The latencies of P100 wave was 132 ms and 127 ms in right and left eye, respectively, so they were prolonged over 20% in both eyes in comparison to normal values. The morphology of the waves was also abnormal (Figure 1). On the basis of PVER, the suspicion of a demyelinating process was established.

The brain MRI with contrast revealed 3 lesions not meeting diagnostic criteria for multiple sclerosis. The orbital MRI with contrast revealed no lesions. A spinal cord MRI showed 1 lesion on the C3/C4 level.

The patient was referred to the neurology ward and a suspicion of Devic’s disease was established. Within 6 weeks after first symptoms (three weeks after ophthalmic examination) the patient presented a weakening of the lower limbs and developed clinical transverse myelitis. The patient was treated by IV steroids. The spinal cord MRI revealed lesions extending over 3 vertebral segments. The diagnosis of Devic’s syndrome was established, which was later confirmed by NMO-IgG seropositive status.

In 4 years’ observation, the visual function remains quite good (6/9 in both eyes), but urinary incontinence and walking disorders significantly worsen the 25-year-old patient’s quality of life.

Discussion

Devic’s disease is considered to be an acute and devastating disease. It was reported that 55.8% of NMO patients need support to walk within 5 years from diagnosis, mortality rate ranges from 2.9% to 25%, and about 50% of patients have severe visual deficits within 5 years from diagnosis [1,8–11]. Although it is very rare disease, its early diagnosis may allow administering proper treatment (IV steroids, plasmapheresis, Imuran, rituximab), thus preventing mortality.

Most papers describe full clinical manifestation of Devic’s disease. Our paper presents a case report of very early NMO diagnosis. In our patient, non-specific ocular phenomena preceded the neurological manifestations. Although the ophthalmologic examination and tests were normal, visual evoked potentials pointed to a demyelinating process. Further diagnostic procedures (brain and spinal cord MRI, neurological consultation) allowed establishing a proper diagnosis.

Conclusions

We would like to emphasize that non-specific ocular symptoms or subjective visual impairment in young patients in their 20s or 30s, with full visual acuity, normal ophthalmic and accessory investigation results, should be examined by visual evoked potentials testing to exclude demyelination. In these cases, it is essential to exclude a neuromyelitis optica, a disease with a worse prognosis than multiple sclerosis.

References

1. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG, The clinical course of neuromyelitis optica (Devic’s syndrome): Neurology, 1999; 53; 1107-14, pmid: 10496275

2. Rivera JF, Kurtzke JF, Booth VJA, Corona T, Characteristics of Devic’s disease (neuromyelitis optica) in Mexico: J Neurol, 2008; 255; 710-15, pmid: 18283393

3. Fazio R, Radaelli M, Furla R, Neuromyelitis optica: Concepts in evolution: J Neuroimmunol, 2011; 231; 100-4, pmid: 21067820

4. Lennon VA, Kryzer TJ, Pittock SJ, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel: J Exp Med, 2005; 202; 473-77, pmid: 16087714

5. Lennon VA, Wingerchuk DM, Kryzer TJ, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis: Lancet, 2004; 364; 2106-12, pmid: 15589308

6. Waters P, Vincent A, Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays: The International MS Journal, 2008; 15; 99-105

7. Wingerchuk DM, Lennon VA, Pittock SS, Revised diagnostic criteria for neuromyelitis optica: Neurology, 2006; 66; 1485-89, pmid: 16717206

8. Bergamaschi R, Ghezzi A, Devic’s neuromyelitis optica: clinical features and prognostic factors: Neurological Sciences, 2004; 25; 364-67

9. Ghezzi A, Bergamaschi R, Martinelli V, Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica: J Neurol, 2004; 251; 47-52, pmid: 14999489

10. Sellner J, Boggild M, Clanet M, EFNS guidelines on diagnosis and management of neuromyelitis optica: Eur J Neurol, 2010; 17; 1019-32, pmid: 20528913

11. Mandler RN, Davis LE, Jeffrey DR, Kornfeld M, Devic’s neuromyelitis optica: a clinopathological study of 8 patients: Ann Neurol, 1993; 34; 162-68, pmid: 8338340

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750